Abstract:ID 18908 Poster Board 186 Pregnane X receptor (PXR, NR1I2), a ligand-activated transcription factor, is relatively abundant in liver and intestine. Previous studies have demonstrated that PXR activation inhibits liver fibrosis, but the specific mechanisms still remain unclear. Leukocyte cell-derived chemotaxin 2 (LECT2), a downstream target of β-catenin/ T cell-specific factor 4 (TCF4) signaling, is a small-molecule protein secreted by hepatocytes. Recent study illustrated that LECT2 produced by hepatocytes participated in the progression of hepatic fibrosis by regulating angiogenesis. In the current study, we aimed to investigate whether PXR activation attenuate liver fibrosis by inhibiting LECT2 and explore its impact on β-catenin/TCF4 signaling. Additionally, we also aimed to unveil the critical role of β-catenin/TCF4-LECT2 axis in liver fibrosis and demonstrate whether PXR activation alleviates hepatic fibrosis via inhibiting β-catenin/TCF4-LECT2 axis. In the current study, carbon tetrachloride (CCl4) was used to induce liver fibrosis in C57BL/6 mice. The results showed that mouse PXR agonist pregnenolone-16α-carbonitrile (PCN) significantly attenuated hepatic fibrosis by suppressing the expression of α-smooth muscle actin (α-SMA), Collagen ? and platelet endothelial cell adhesion molecule-1 (CD31). Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) and CD31 staining indicated that PXR activation inhibited sinusoids capillarization and central angiogenesis. Besides, immunohistochemical (IHC) staining and western blot analysis indicated that LECT2 and nuclear β-catenin were significantly downregulated after PXR activation, while total β-catenin and TCF4 didn’t alter significantly. Furthermore, reporter gene assay was performed and suggested that PXR activation inhibited the transcriptional activation of LECT2 by β-catenin/TCF4. PXR activation disrupted the interaction between β-catenin and TCF4. Co-Immunoprecipitation (Co-IP) assays further indicated that PXR potentially interacted with β-catenin and TCF4 simultaneously. Moreover, to clarify whether disrupting β-catenin/TCF4 interaction alleviated liver fibrosis, β-catenin/TCF4 inhibitor LF3 was used to evaluate its effect on liver fibrosis. The results showed the inhibition of β-catenin/TCF4 interaction decreased the expression level of LECT2 and alleviated liver fibrosis. In addition, AAV-Lect2 mice was used and we found that PXR activation failed to protect liver from fibrosis in AAV-Lect2 mice, which further confirmed that PXR attenuated hepatic fibrosis by inhibiting LECT2. Finally, we clarified that long-term treatment of PCN had no risk for carcinogenesis or promoting tumor formation induced by diethylnitrosamine (DEN), indicating the safety of long-term activation of PXR. Taken together, this study demonstrated a new mechanism that PXR attenuated liver fibrosis by disrupting β-catenin/TCF4 interaction and suppressing the expression level of LECT2. The crosstalk between PXR and β-catenin/TCF4 signaling was also clarified. These findings provide new evidence and theoretical basis for PXR as potential drug target for liver fibrosis.

PPARβ/δ attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells

Peroxisome Proliferator-Activated Receptors Gamma Reverses Hepatic Nutritional Fibrosis in Mice and Suppresses Activation of Hepatic Stellate Cells in Vitro.

Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats.

PPAR Gamma Inhibits Growth of Rat Hepatic Stellate Cells and TGF Beta-Induced Connective Tissue Growth Factor Expression

PGC1 protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response

PGC1α protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response.

Regulation of Peroxisome Proliferator-Activated Receptor-Gamma Activity Affects the Hepatic Stellate Cell Activation and the Progression of NASH Via TGF-β1/Smad Signaling Pathway

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

Deletion of GPR81 Activates CREB/Smad7 Pathway and Alleviates Liver Fibrosis in Mice

Leptin inhibits PPARgamma gene expression in hepatic stellate cells in the mouse model of liver damage.

Peroxisome Proliferator-Activated Receptor-Γ Cross-Regulation of Signaling Events Implicated in Liver Fibrogenesis

PPARs: Modulating Lipotoxicity and Thus Inhibiting Fibrosis

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.

Peroxisome Proliferator-Activated Receptor-γ(PPAR-γ) Agonists Attenuate the Profibrotic Response Induced by TGF-β1 in Renal Interstitial Fibroblasts

Paeoniflorin promotes PPARγ expression to suppress HSCs activation by inhibiting EZH2-mediated histone H3K27 trimethylation

Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and liver fibrosis by epigenetically regulating peroxisome proliferator-activated receptor γ

PXR Activation Attenuates Liver Fibrosis by Down-Regulating LECT2 and Disrupting -Catenin/tcf4 Interaction

Peroxisome Proliferator–Activated Receptor Δ Agonist GW1516 Attenuates Diet-Induced Aortic Inflammation, Insulin Resistance, and Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice

Regulation of the Macrophage-Hepatic Stellate Cell Interaction by Targeting Macrophage Peroxisome Proliferator-Activated Receptor Gamma to Prevent Non-Alcoholic Steatohepatitis Progression in Mice

[The Role of Peroxisome Proliferators-Activated Receptor Gamma (ppargamma) During Activation of Hepatic Stellate Cells].